Myriad Genetics
MYGN
223 hedge funds and large institutions have $2.25B invested in Myriad Genetics in 2024 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 72 increasing their positions, 64 reducing their positions, and 15 closing their positions.
260% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 15
56% more call options, than puts
Call options by funds: $4.84M | Put options by funds: $3.1M
20% more funds holding
Funds holding: 186 → 223 (+37)
13% more capital invested
Capital invested by funds: $2B → $2.25B (+$254M)
13% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 64
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.54% less ownership
Funds ownership: 104.41% → 101.87% (-2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$18.9M |
| 2 |
JP Morgan Chase
New York
|
+$10.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$8.72M |
| 4 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
+$7.91M |
| 5 |
Millennium Management
New York
|
+$7.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$46.8M |
| 2 |
GCM
Glenview Capital Management
New York
|
-$26.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$23.3M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$14.7M |
| 5 |
State Farm Mutual Automobile Insurance
Bloomington,
Illinois
|
-$9.51M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
226
American International Group
New York
| – | -$1.01M | -47,331 | Closed |
|
|
PVI
227
Pura Vida Investments
New York
| – | -$954K | -44,725 | Closed |
|
228
Marshall Wace
London,
United Kingdom
| – | -$715K | -33,557 | Closed |
|
|
TI
229
Tidal Investments
Milwaukee,
Wisconsin
| – | -$606K | -28,432 | Closed |
|
230
SG Americas Securities
New York
| – | -$465K | -21,805 | Closed |
|
231
Two Sigma Investments
New York
| – | -$435K | -20,400 | Closed |
|
|
FRM
232
Fox Run Management
Greenwich,
Connecticut
| – | -$365K | -17,120 | Closed |
|
233
Allianz Asset Management
Munich,
Germany
| – | -$348K | -16,300 | Closed |
|
|
EFM
234
E Fund Management
Guangzhou,
China
| – | -$251K | -11,776 | Closed |
|
|
MLICM
235
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$98.5K | -4,619 | Closed |
|
|
ST
236
Smithfield Trust
Pittsburgh,
Pennsylvania
| – | -$2K | -84 | Closed |
|
|
AWM
237
Avior Wealth Management
Omaha,
Nebraska
| – | -$341 | -16 | Closed |
|
MYGN Hedge Fund Activity: Q2 2024 in Review
223 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2024, worth a combined $2.25B — up 13% from $2B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new MYGN positions and 15 closed out — a net gain of 39 holders — while 72 added to existing stakes and 64 trimmed.
The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $18.9M. The largest seller was Camber Capital Management, cutting an estimated $46.8M.
- 223 institutional investors held Myriad Genetics (MYGN) as of Q2 2024, up from 186 in Q1 2024.
- Funds reported $2.25B of Myriad Genetics stock for Q2 2024, up 13% quarter-over-quarter.
- 54 funds opened new Myriad Genetics positions in Q2 2024 and 15 closed out, a net change of +39 holders.
- The largest Myriad Genetics buyer in Q2 2024 was Loomis, Sayles & Company, an estimated $18.9M added.
- The largest Myriad Genetics seller in Q2 2024 was Camber Capital Management, an estimated $46.8M sold.
Based on aggregated 13F filings for Q2 2024.